Mark Christopher Markowski, MD, PhD, discusses phase 1b/2 data for the novel oral cytoskeletal disruptor VERU-111 in metastatic castration-resistant prostate cancer (mCRPC) being presented during the 2021 ASCO Annual Meeting. Markowski, the lead study author and assistant professor of oncology at Johns Hopkins Medicine, also comments on where VERU-111 might fit in the mCRPC treatment sequence. (J Clin Oncol 39, 2021 [suppl 15; abstr 5056]. doi: 10.1200/JCO.2021.39.15_suppl.5056)
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.